Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ASS1

Gene summary for ASS1

Gene summary.

Gene information	Species	Human
	Gene symbol	ASS1
	Gene ID	445
	Gene name	argininosuccinate synthase 1
	Gene Alias	ASS
	Cytomap	9q34.11
	Gene Type	protein-coding
	GO ID	GO:0000050
	UniProtAcc	P00966

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
445	ASS1	HTA11_3410_2000001011	Human	Colorectum	AD	2.75e-06	4.09e-01	0.0155
445	ASS1	HTA11_2487_2000001011	Human	Colorectum	SER	3.83e-26	1.56e+00	-0.1808
445	ASS1	HTA11_1938_2000001011	Human	Colorectum	AD	4.81e-12	1.02e+00	-0.0811
445	ASS1	HTA11_78_2000001011	Human	Colorectum	AD	5.84e-09	7.92e-01	-0.1088
445	ASS1	HTA11_347_2000001011	Human	Colorectum	AD	1.68e-23	8.04e-01	-0.1954
445	ASS1	HTA11_411_2000001011	Human	Colorectum	SER	2.22e-10	2.03e+00	-0.2602
445	ASS1	HTA11_2112_2000001011	Human	Colorectum	SER	1.41e-16	1.85e+00	-0.2196
445	ASS1	HTA11_3361_2000001011	Human	Colorectum	AD	8.59e-11	7.77e-01	-0.1207
445	ASS1	HTA11_83_2000001011	Human	Colorectum	SER	3.58e-05	7.37e-01	-0.1526
445	ASS1	HTA11_696_2000001011	Human	Colorectum	AD	1.15e-45	1.30e+00	-0.1464
445	ASS1	HTA11_866_2000001011	Human	Colorectum	AD	4.61e-14	7.44e-01	-0.1001
445	ASS1	HTA11_1391_2000001011	Human	Colorectum	AD	2.11e-42	1.76e+00	-0.059
445	ASS1	HTA11_2992_2000001011	Human	Colorectum	SER	5.68e-11	1.04e+00	-0.1706
445	ASS1	HTA11_5212_2000001011	Human	Colorectum	AD	1.94e-10	1.00e+00	-0.2061
445	ASS1	HTA11_546_2000001011	Human	Colorectum	AD	1.07e-04	6.59e-01	-0.0842
445	ASS1	HTA11_866_3004761011	Human	Colorectum	AD	5.92e-03	3.72e-01	0.096
445	ASS1	HTA11_10711_2000001011	Human	Colorectum	AD	6.55e-08	6.67e-01	0.0338
445	ASS1	HTA11_7696_3000711011	Human	Colorectum	AD	1.45e-15	7.57e-01	0.0674
445	ASS1	HTA11_6818_2000001011	Human	Colorectum	AD	2.07e-06	6.38e-01	0.0112
445	ASS1	HTA11_99999970781_79442	Human	Colorectum	MSS	1.25e-06	4.58e-01	0.294

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00086521	Liver	Cirrhotic	cellular amino acid biosynthetic process	36/4634	76/18723	1.55e-05	2.11e-04	36
GO:19016071	Liver	Cirrhotic	alpha-amino acid biosynthetic process	33/4634	68/18723	1.84e-05	2.49e-04	33
GO:000756812	Liver	Cirrhotic	aging	117/4634	339/18723	3.13e-05	3.91e-04	117
GO:19016551	Liver	Cirrhotic	cellular response to ketone	42/4634	96/18723	3.55e-05	4.32e-04	42
GO:000758411	Liver	Cirrhotic	response to nutrient	67/4634	174/18723	3.83e-05	4.59e-04	67
GO:0071346	Liver	Cirrhotic	cellular response to interferon-gamma	49/4634	118/18723	4.43e-05	5.22e-04	49
GO:004851111	Liver	Cirrhotic	rhythmic process	103/4634	298/18723	8.47e-05	9.19e-04	103
GO:000657511	Liver	Cirrhotic	cellular modified amino acid metabolic process	70/4634	188/18723	9.04e-05	9.69e-04	70
GO:00715481	Liver	Cirrhotic	response to dexamethasone	21/4634	39/18723	9.13e-05	9.74e-04	21
GO:00346126	Liver	Cirrhotic	response to tumor necrosis factor	89/4634	253/18723	1.24e-04	1.22e-03	89
GO:00011013	Liver	Cirrhotic	response to acid chemical	52/4634	135/18723	2.65e-04	2.36e-03	52
GO:00715491	Liver	Cirrhotic	cellular response to dexamethasone stimulus	16/4634	29/18723	4.36e-04	3.55e-03	16
GO:00432002	Liver	Cirrhotic	response to amino acid	45/4634	116/18723	5.54e-04	4.36e-03	45
GO:00713566	Liver	Cirrhotic	cellular response to tumor necrosis factor	79/4634	229/18723	5.68e-04	4.45e-03	79
GO:00069531	Liver	Cirrhotic	acute-phase response	23/4634	49/18723	6.06e-04	4.67e-03	23
GO:200105712	Liver	Cirrhotic	reactive nitrogen species metabolic process	34/4634	82/18723	6.36e-04	4.85e-03	34
GO:007139811	Liver	Cirrhotic	cellular response to fatty acid	19/4634	38/18723	6.75e-04	5.06e-03	19
GO:00324966	Liver	Cirrhotic	response to lipopolysaccharide	111/4634	343/18723	8.15e-04	5.95e-03	111
GO:005159112	Liver	Cirrhotic	response to cAMP	37/4634	93/18723	9.58e-04	6.78e-03	37
GO:004620912	Liver	Cirrhotic	nitric oxide metabolic process	33/4634	81/18723	1.09e-03	7.59e-03	33

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05418	Colorectum	AD	Fluid shear stress and atherosclerosis	54/2092	139/8465	1.41e-04	1.16e-03	7.37e-04	54
hsa01230	Colorectum	AD	Biosynthesis of amino acids	28/2092	75/8465	9.99e-03	3.89e-02	2.48e-02	28
hsa054181	Colorectum	AD	Fluid shear stress and atherosclerosis	54/2092	139/8465	1.41e-04	1.16e-03	7.37e-04	54
hsa012301	Colorectum	AD	Biosynthesis of amino acids	28/2092	75/8465	9.99e-03	3.89e-02	2.48e-02	28
hsa054182	Colorectum	SER	Fluid shear stress and atherosclerosis	40/1580	139/8465	2.28e-03	1.75e-02	1.27e-02	40
hsa012302	Colorectum	SER	Biosynthesis of amino acids	23/1580	75/8465	8.11e-03	4.14e-02	3.01e-02	23
hsa054183	Colorectum	SER	Fluid shear stress and atherosclerosis	40/1580	139/8465	2.28e-03	1.75e-02	1.27e-02	40
hsa012303	Colorectum	SER	Biosynthesis of amino acids	23/1580	75/8465	8.11e-03	4.14e-02	3.01e-02	23
hsa054184	Colorectum	MSS	Fluid shear stress and atherosclerosis	51/1875	139/8465	6.06e-05	5.80e-04	3.55e-04	51
hsa054185	Colorectum	MSS	Fluid shear stress and atherosclerosis	51/1875	139/8465	6.06e-05	5.80e-04	3.55e-04	51
hsa05418211	Esophagus	ESCC	Fluid shear stress and atherosclerosis	109/4205	139/8465	2.00e-12	3.72e-11	1.90e-11	109
hsa0123023	Esophagus	ESCC	Biosynthesis of amino acids	49/4205	75/8465	4.35e-03	1.12e-02	5.74e-03	49
hsa05418310	Esophagus	ESCC	Fluid shear stress and atherosclerosis	109/4205	139/8465	2.00e-12	3.72e-11	1.90e-11	109
hsa0123033	Esophagus	ESCC	Biosynthesis of amino acids	49/4205	75/8465	4.35e-03	1.12e-02	5.74e-03	49
hsa0541814	Liver	NAFLD	Fluid shear stress and atherosclerosis	30/1043	139/8465	1.37e-03	1.71e-02	1.38e-02	30
hsa0541815	Liver	NAFLD	Fluid shear stress and atherosclerosis	30/1043	139/8465	1.37e-03	1.71e-02	1.38e-02	30
hsa0541822	Liver	Cirrhotic	Fluid shear stress and atherosclerosis	62/2530	139/8465	1.53e-04	1.06e-03	6.54e-04	62
hsa012304	Liver	Cirrhotic	Biosynthesis of amino acids	35/2530	75/8465	1.54e-03	7.83e-03	4.83e-03	35
hsa0541832	Liver	Cirrhotic	Fluid shear stress and atherosclerosis	62/2530	139/8465	1.53e-04	1.06e-03	6.54e-04	62
hsa0123011	Liver	Cirrhotic	Biosynthesis of amino acids	35/2530	75/8465	1.54e-03	7.83e-03	4.83e-03	35

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ASS1

SNV

Missense_Mutation

c.836G>C

p.Arg279Pro

p.R279P

P00966

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-A1-A0SO-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

ASS1

insertion

Nonsense_Mutation

novel

c.938_939insACGGTGAGGCCTGAGGAACTCCCGAGGGATTTGA

p.Gly314ArgfsTer2

p.G314Rfs*2

P00966

protein_coding

TCGA-BH-A0HX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adrimycin

ASS1

SNV

Missense_Mutation

rs771937610

c.1088N>A

p.Arg363Gln

p.R363Q

P00966

protein_coding

deleterious(0.04)

benign(0.164)

TCGA-FU-A23K-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

ASS1

SNV

Missense_Mutation

rs183276875

c.919N>T

p.Arg307Cys

p.R307C

P00966

protein_coding

tolerated(0.06)

possibly_damaging(0.85)

TCGA-AA-3663-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

ASS1

SNV

Missense_Mutation

c.440N>C

p.Met147Thr

p.M147T

P00966

protein_coding

tolerated(0.31)

benign(0.015)

TCGA-AA-A01R-01

Colorectum

colon adenocarcinoma

Male

<65

III/IV

Chemotherapy

5-fluorouracil

ASS1

SNV

Missense_Mutation

c.856N>A

p.Ala286Thr

p.A286T

P00966

protein_coding

deleterious(0)

probably_damaging(0.949)

TCGA-F4-6856-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Ancillary

leucovorin

ASS1

SNV

Missense_Mutation

novel

c.637N>G

p.Pro213Ala

p.P213A

P00966

protein_coding

deleterious(0.02)

possibly_damaging(0.801)

TCGA-AG-3881-01

Colorectum

rectum adenocarcinoma

Female

>=65

I/II

Unknown

ASS1

SNV

Missense_Mutation

c.717N>T

p.Lys239Asn

p.K239N

P00966

protein_coding

tolerated(0.32)

benign(0.009)

TCGA-AG-A002-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

ASS1

SNV

Missense_Mutation

novel

c.627N>T

p.Lys209Asn

p.K209N

P00966

protein_coding

tolerated(0.08)

possibly_damaging(0.734)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

ASS1

SNV

Missense_Mutation

novel

c.896N>T

p.Ala299Val

p.A299V

P00966

protein_coding

tolerated(0.19)

benign(0.003)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
445	ASS1	ENZYME, DRUG RESISTANCE		CHLOROQUINE	CHLOROQUINE	27735949
445	ASS1	ENZYME, DRUG RESISTANCE		PLATINUM COMPOUND		19533750
445	ASS1	ENZYME, DRUG RESISTANCE		Sodium Phenylbutyrate
445	ASS1	ENZYME, DRUG RESISTANCE		sodium phenylbutyrate
445	ASS1	ENZYME, DRUG RESISTANCE		sodium benzoate / sodium phenylacetate
445	ASS1	ENZYME, DRUG RESISTANCE		PEGARGIMINASE	PEGARGIMINASE	27735949

Page: 1